Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
   PubMed Web of Science ®Google Scholar
• Sohal DPS, Mangu PB, Laheru D. Metastatic pancreatic cancer: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2017;13(4):261–264.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-Paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ, Bertucci F, Finetti P, et al. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2018;1869(2):248–255.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Templeton AJ, Maganti M, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50(9):1581–1589.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-Lymphocyte ratio in solid tumors: a systematic review and Meta-Analysis. JNCI J Natl Cancer Inst. 2014;106(6):dju124.
   Web of Science ®Google Scholar
• Wang D, Luo H, Qiu M, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29(5):3092–3100.
   PubMed Web of Science ®Google Scholar
• An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15(6):516–522.
   PubMed Web of Science ®Google Scholar
• Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197(4):466–472.
   PubMed Web of Science ®Google Scholar
• Vivaldi C, Caparello C, Musettini G, et al. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: patients’ outcome and analysis of prognostic factors. Int J Cancer. 2016;139(4):938–945.
   PubMed Web of Science ®Google Scholar
• Franco F, Camara JC, Martín-Valadés JI, et al. Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting. Clin Transl Oncol. 2020;23:812–819.
   PubMed Web of Science ®Google Scholar
• Pacheco-Barcia V, Mondéjar Solís R, France T, et al. A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology. 2020;20(2):254–264.
   PubMed Web of Science ®Google Scholar
• Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158–2167.
   PubMed Web of Science ®Google Scholar
• Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2010;98(2):268–274.
   Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35.
   PubMed Web of Science ®Google Scholar
• Khomiak A, Brunner M, Kordes M, et al. Recent discoveries of diagnostic, prognostic and predictive biomarkers for pancreatic cancer. Cancers (Basel). 2020;12(11):3234.
   PubMed Web of Science ®Google Scholar
• Wei L, Xie H, Yan P. Prognostic value of the systemic inflammation response index in human malignancy. Medicine (Baltimore). 2020;99(50):e23486.
   PubMed Web of Science ®Google Scholar
• Li S, Xu H, Wang W, et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res. 2019;11:3327–3337.
   PubMed Web of Science ®Google Scholar
• Chan KKW, Guo H, Cheng S, et al. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis. Cancer Med. 2020;9(1):160–169.
   PubMed Web of Science ®Google Scholar
• Chllamma MK, Cook N, Dhani NC, et al. FOLFIRINOX for advanced pancreatic cancer: the princess margaret cancer Centre experience. Br J Cancer. 2016;115(6):649–654.
   PubMed Web of Science ®Google Scholar
• Topkan E, Mertsoylu H, Kucuk A, et al. Low systemic inflammation response index predicts good prognosis in locally advanced pancreatic carcinoma patients treated with concurrent chemoradiotherapy. Gastroenterol Res Pract. 2020;2020:5701949.
   PubMed Web of Science ®Google Scholar
• Lafaro KJ, Melstrom LG. The paradoxical web of pancreatic cancer tumor microenvironment. Am J Pathol. 2019;189(1):44–57.
   PubMed Web of Science ®Google Scholar
• Steele CW, Gill NAK, Jamieson NB, et al. Targeting inflammation in pancreatic cancer: clinical translation. World J Gastrointest Oncol. 2016;8(4):380–388.
   PubMed Web of Science ®Google Scholar